Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies
Author:
Affiliation:
1. Department of Hematology; Mayo Clinic Foundation; Rochester Minnesota
2. Department of Health Sciences Research; Mayo Clinic Foundation; Rochester Minnesota
3. Department of General Internal Medicine; Mayo Clinic Foundation; Rochester Minnesota
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28340/fullpdf
Reference54 articles.
1. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients;Belch;Br J Cancer.,1988
2. Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment;Cohen;J Clin Oncol.,1986
3. Report on the second myelomatosis trial after 5 years of follow-up. Medical Research Council's Working Party on Leukaemia in Adults;Br J Cancer.,1980
4. Treatment comparisons in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults;Br J Cancer.,1980
5. Remission maintenance therapy for multiple myeloma;Alexanian;Arch Intern Med.,1975
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma—a single-centre, qualitative service evaluation study;Supportive Care in Cancer;2024-07
2. Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma;PharmacoEconomics - Open;2019-10-11
3. Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial;British Journal of Haematology;2018-05-17
4. Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent;Expert Review of Hematology;2017-09-25
5. Patient Reported Outcomes in Optimizing Myeloma Patients' Health-Related Quality of Life;Seminars in Oncology Nursing;2017-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3